Evidence beyond compare
In an assessment conducted by the National Institute for Health and Care Excellence (NICE) evaluating the quality of data for dermal substitute studies in diabetic foot ulcers, GRAFIX◊ Cryopreserved Placental Membrane had the highest overall effect and was the only dermal substitute determined to have high quality of evidence with no serious risk of bias.2-4
62% of DFUs (n=97) closed with GRAFIX Membrane at 12 weeks vs. 21% with standard of care alone (p=0.0001)24,25
59% of complex DFUs (n=27) closed with GRAFIX Membrane at 16 weeks26
53% of VLUs that failed to close with 12 weeks SOC went on to close with GRAFIX Membrane + standard of care (p<0.001)27
59% of DFUs (n=350) closed with GRAFIX Membrane30
76% of chronic wounds (n=67) closed with GRAFIX Membrane at 12 weeks34
59% of chronic wounds (n=98) achieved complete wound closure with GRAFIX PL Membrane28
63% of chronic wounds (n=40) closed with GRAFIX Membrane29
18% of chronic wounds (n=39) closed with EpiFix™ (p<0.0001)29
For DFUs ≤5 cm2, significantly more patients achieved complete wound closure with GRAFIX PRIME Membrane compared with Dermagraft®36
A closer look at the use of Placental Membranes for wound closure
View a summary of this clinical evidence here.